Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Encompass Health (EHC) due to higher revenues, with a focus on how actual results will compare to estimates impacting stock price [1][2]. Earnings Expectations - Encompass Health is expected to report quarterly earnings of $1.20 per share, reflecting an 8.1% increase year-over-year, with revenues projected at $1.43 billion, a 9.7% rise from the previous year [3]. - The earnings report is scheduled for August 4, and better-than-expected results could lead to a stock price increase, while disappointing results may cause a decline [2]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a stable outlook from covering analysts [4]. - The Most Accurate Estimate for Encompass Health is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -0.24%, suggesting a bearish sentiment among analysts [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive Earnings ESP is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10]. - Encompass Health currently holds a Zacks Rank of 2, but the negative Earnings ESP complicates predictions for beating the consensus EPS estimate [12]. Historical Performance - Encompass Health has consistently beaten consensus EPS estimates, achieving this in the last four quarters [14]. - In the last reported quarter, the company exceeded expectations by delivering earnings of $1.37 per share against an expected $1.19, resulting in a surprise of +15.13% [13]. Conclusion - While Encompass Health does not appear to be a compelling earnings-beat candidate, investors should consider various factors beyond earnings results when making investment decisions [17].

Wall Street expects a year-over-year decline in earnings on lower revenues when MSA Safety (MSA) reports results for the quarter ended June 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on August 4, might help the stock move higher if these key numbers are better than expectations. O ...

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. Oneok Inc. (OKE) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but ho ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Marriott Vacations Worldwide (VAC) reports results for the quarter ended June 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. Price, Consensus and EPS Surprise Earnings Whisper The earnings report, which is expected to be released on August 4, might help the ...

Core Viewpoint - V2X (VVX) is anticipated to report a year-over-year increase in earnings despite lower revenues, which could significantly influence its near-term stock price depending on how actual results compare to consensus estimates [1][2]. Earnings Expectations - The upcoming earnings report is expected to be released on August 4, with a consensus estimate of $1.00 per share, reflecting a year-over-year increase of +20.5%. Revenues are projected to be $1.04 billion, down 3.1% from the previous year [3][2]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating that analysts have not significantly altered their initial projections during this period [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that V2X has a positive Earnings ESP of +4.17%, suggesting analysts have recently become more optimistic about the company's earnings prospects. However, the stock holds a Zacks Rank of 4, complicating predictions of an earnings beat [12]. Historical Performance - In the last reported quarter, V2X was expected to earn $0.92 per share but exceeded expectations with earnings of $0.98, resulting in a surprise of +6.52%. Over the last four quarters, the company has beaten consensus EPS estimates three times [13][14]. Conclusion - While V2X does not appear to be a strong candidate for an earnings beat, it is essential for investors to consider other factors when making decisions regarding the stock ahead of the earnings release [17].

The market expects Williams Companies, Inc. (The) (WMB) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expect ...

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Atlas Energy Solutions Inc. (AESI) despite higher revenues, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - The upcoming earnings report is expected on August 4, with a consensus estimate of $0.14 per share, reflecting a year-over-year decrease of 12.5%. Revenues are projected to be $301.24 million, an increase of 4.8% from the previous year [3]. - The consensus EPS estimate has been revised down by 9.21% over the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model shows a positive Earnings ESP of +11.11% for Atlas Energy Solutions, suggesting recent bullish sentiment among analysts [12]. - However, the company holds a Zacks Rank of 5 (Strong Sell), complicating predictions of an earnings beat [12]. Historical Performance - In the last reported quarter, Atlas Energy Solutions was expected to earn $0.18 per share but only achieved $0.08, resulting in a surprise of -55.56% [13]. - The company has not surpassed consensus EPS estimates in any of the last four quarters [14]. Industry Comparison - Cactus, Inc. (WHD), a peer in the oil and gas sector, is expected to report an EPS of $0.67, down 17.3% year-over-year, with revenues projected at $275.61 million, a decrease of 5.1% [18]. - Cactus has a Zacks Rank of 5 and an Earnings ESP of 0%, making it similarly challenging to predict an earnings beat [20].

Core Viewpoint - Ambac Financial Group (AMBC) is expected to report a year-over-year decline in earnings due to lower revenues, with a consensus outlook indicating a quarterly loss of $0.24 per share, representing a -233.3% change from the previous year [1][3]. Earnings Expectations - The upcoming earnings report is crucial for stock movement; better-than-expected results could drive the stock higher, while a miss may lead to a decline [2]. - The consensus estimate for revenues is projected at $55.59 million, down 47.1% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 25% higher in the last 30 days, reflecting a reassessment by analysts [4]. - Ambac's Most Accurate Estimate is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +12.50%, indicating a likelihood of beating the consensus EPS estimate [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a favorable Zacks Rank [10]. - Ambac currently holds a Zacks Rank of 3, which indicates a neutral outlook, but the positive Earnings ESP suggests potential for an earnings surprise [12]. Historical Performance - Ambac has not been able to beat consensus EPS estimates in any of the last four quarters, with the last reported quarter showing a significant miss of -85.71% [13][14]. Industry Comparison - Skyward Specialty Insurance (SKWD), another player in the insurance industry, is expected to report a year-over-year EPS increase of +7.5% and has a positive Earnings ESP of +2.51%, indicating a likely earnings beat [18][19].

Core Insights - S&P Global Inc. (SPGI) is set to release its second-quarter 2025 results on July 31, with a history of surpassing earnings estimates, averaging a surprise of 7.5% over the past four quarters [1][9]. Revenue Expectations - The Zacks Consensus Estimate for SPGI's revenues is $3.7 billion, reflecting a 3.7% increase from the same quarter last year, driven by strong core product demand and effective marketing initiatives [2][10]. - Market Intelligence revenues are projected at $1.2 billion, indicating a 3.7% year-over-year growth, supported by strong data analytics performance and positive M&A contributions [3][10]. - Ratings revenues are estimated at $1.1 billion, slightly above last year's figure, benefiting from increased issuance and refinancing activity [4]. - Commodity Insights revenues are expected to reach $539.8 million, showing a 4.6% year-over-year growth, aided by high demand for data and insights [5]. - Mobility revenues are projected at $420.1 million, reflecting a 5% increase from the previous year, driven by strong demand for CARFAX and effective marketing [6]. - Indices revenues are estimated at $397.2 million, implying a 2.1% year-over-year increase, primarily due to strong asset-linked fee growth [7]. Profitability Metrics - Adjusted EBITDA is estimated at $2.1 billion for the quarter, up 2.5% from the previous year, driven by top-line growth and strategic expense management [8]. - The consensus estimate for earnings per share is $4.25, indicating a 5.2% year-over-year increase, likely supported by margin expansion [8][10]. Earnings Prediction - The model predicts an earnings beat for SPGI, with an Earnings ESP of +0.52% and a Zacks Rank of 2 (Buy), enhancing the likelihood of exceeding earnings expectations [9].

Core Viewpoint - Bristol-Myers Squibb Company (BMY) is set to report its second-quarter 2025 results on July 31, with sales and earnings estimates at $11.38 billion and $1.18 per share, respectively. However, earnings estimates for 2025 and 2026 have seen a decline over the past month [1][5]. Financial Estimates - The current earnings estimate for Q2 2025 is $1.18, down from $1.55 30 days ago, reflecting a decrease of 29.34%. The earnings estimates for 2025 and 2026 have also decreased to $6.37 and $6.03, respectively [2][5]. - BMY has a strong earnings surprise history, beating estimates in the last four quarters with an average surprise of 20.16% [2]. Factors Influencing Q2 Results - Total quarterly revenues are expected to be negatively impacted by declining sales from the legacy portfolio, which includes drugs like Eliquis, Revlimid, and Pomalyst, primarily due to generic competition [4][5]. - Sales for Pomalyst are estimated at $727 million, while Eliquis is projected to generate $3.5 billion in sales [6][7]. Growth Portfolio Performance - The growth portfolio, which includes drugs like Opdivo, Reblozyl, and Camzyos, is expected to partially offset the decline in legacy drug sales. Opdivo sales are estimated at $2.4 billion, while Reblozyl is projected at $546 million [8][10][11]. - New drug Cobenfy for schizophrenia has shown promising sales growth, indicating a positive start for the newly launched product [12][18]. Strategic Initiatives - BMY has announced cost-cutting plans aiming to save $1.5 billion by 2025 and an additional $2 billion annually by 2027, which are expected to improve profitability [5][14]. - The company has entered a strategic collaboration with BioNTech for the co-development of a bispecific antibody, BNT327, which targets solid tumors [19][22]. Stock Performance and Valuation - BMY shares have declined by 14.4% year-to-date, underperforming the industry and the S&P 500 [16]. - The stock currently trades at a price/earnings ratio of 7.84x forward earnings, lower than its historical mean and the large-cap pharma industry average [20].